The Corvidia Approach

Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company’s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia’s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. This approach confers unique concepts within the field of cardiovascular medicines and an unprecedented accelerated path-to-market. Corvidia brings together a team of distinguished scientists, experienced drug developers as the management team, and a successful group of investors. Corvidia is headquartered in the Greater Boston area.

Management Team

Board of Directors

Michael Davidson – CEO

Graziano Seghezzi – Sofinnova Partners

Graziano Seghezzi is a Partner at Sofinnova Partners which he joined in 2006. He seeded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano also seeded and is on the Board of MISSION Therapeutics (United Kingdom), Crescendo Biologics (United Kingdom) and Hookipa Biotech (Austria). He promoted and is on the Board of BiovelocITA, Italy’s first biotech accelerator. Graziano started his career in venture capital in 2001 at Sofinnova Partners and then joined Index Venture in 2003. Prior to that, Graziano spent five years working in academic research at New York University’s School of Medicine, studying oncology and cardiovascular diseases. Graziano holds a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from RSM-Erasmus University (Netherlands).

Seth Harrison – Apple Tree Partners

Seth Harrison is the managing partner of Apple Tree Partners and serves as Executive Chairman of Braeburn Pharmaceuticals. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He is currently also Chairman of Tokai Pharmaceuticals, Chairman of Aileron Therapeutics and Deputy Chairman of Heartware International, all companies he founded. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York. From 2002 – 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.

Adrien Lemoine - AstraZeneca

Adrien Lemoine is an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for mergers and acquisitions, divestments, and strategic equity investments. Prior to joining AstraZeneca in 2015, Adrien was leading strategy and operations at GlaxoSmithKline’s Rare Diseases Unit and was a member of the Advisory Committee of Kurma BioFund II, a rare diseases focused venture capital fund. His earlier experience include roles of increasing responsibility at GlaxoSmithKline in commercial and portfolio analysis functions, and management roles in the strategy consulting industry advising and supporting biotechnology entrepreneurs. Adrien earned his MSc in Engineering and Physical Science in Medicine from the Imperial College (London, UK) and his Master’s degree in Engineering from Supélec (Paris, France).


Press release:

Corvidia Therapeutics Raises $26M Series A Financing


Seeking motivated, self directed, interested in changing the paradigm of cardiovascular diseases.
For more info contact –